Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts
Combination Lipid-Lowering Therapy Linked to Greater Drop in LDL-C
Greater reduction seen in LDL-C; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume of ≥35 percent from baseline
Kansas and Ohio Report Surge in Measles Cases Amid Outbreaks
Even without these two expanding clusters, the total number of cases in the U.S. has exceeded the case count for the entire year of 2024
Heart Failure Patients With Ejection Fraction Improvement Rarely Withdrawn From Meds
Withdrawing renin-angiotensin inhibitors/angiotensin receptor-neprilysin inhibitors and mineralocorticoid receptor antagonists tied to higher one-year mortality, morbidity
Coverage for Routine Childhood Vaccines Remains Below Prepandemic Levels
Vaccine series completion for rotavirus, DTaP, PCV at 12 months was highest in January 2020 and remained lower in October 2023
Federal Government Pulls Back $11.4 Billion in COVID Health Funds
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest
FDA Approves Blujepa for Uncomplicated Urinary Tract Infections
Medication approved for uUTIs in women and pediatric patients aged 12 years and older
